Recall
FDAHealthNovember 21, 2025

Glenmark Pharmaceuticals Inc., USA — Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 2.5 mg/6.25 mg, packaged as (a) 30-count bottles, NDC-68462-878-30; (b) 100-count bottle, NDC-68462-878-0

⚠️ Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe

Is this relevant to me?

Geography
Nationwide
Source agency
FDA
Category
Health
Published
November 21, 2025

Nationwide in the USA

What's affected?

Product
Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 2.5 mg/6.25 mg, packaged as (a) 30-count bottles, NDC-68462-878-30; (b) 100-count bottle, NDC-68462-878-01; (c) 500-count bottles, NDC-68462-878-05; Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, Inda. Manufactured for: Glenmark Pharmaceuticals, Inc., USA, Mahwah, NJ 07430.
UPC
0368462880302
Lot code
(a):

Additional details

Lot #: (a): Lot 17232401, exp 11/2025; Lot 17240974, exp 05/2026 (b): Lot 17232401, exp 11/2025; Lot 17240974, exp 05/2026 (c): Lot 17232401, exp 11/2025; Lot 17240974, exp 05/2026

What should I do?

Recommended action

Class III recall. Voluntary: Firm initiated Quantity affected: 11,136 bottles.

View original FDA notice →

Get Health recall alerts

Delivered to your inbox. Free. No account required.